Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Blood and biopsy sampling

"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."

Trial Locations (1)

69310

Service de Dermatologie, Centre Hospitalier Lyon Sud (HCL), Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03225365 - Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma | Biotech Hunter | Biotech Hunter